high dose oral semaglutide Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) The Top 10 Weight Loss

We report a rare case of acute SBO due to a bezoar in a 65-year-old woman who had been on semaglutide, a Glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss

, : Megha Meena #stellarix #glp1 #pharma #biotech

GLP-1 (glucagon-like peptide-1) medications are a class of drugs used to treat type 2 diabetes and obesity

Find expert care for GLP-1 Therapy in Corona, California with Mounjaro (Tirzepatide)

GLP-1 weight-loss drugs pose hidden risks for young women Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers

Both compounds belong to the growing class of incretin-based weight loss medications that target GLP-1, GIP, and glucagon receptors to help patients lose weight, improve blood sugar control, and reduce liver fat